Society management

Eastern NeuroRadiology Society (ENRS 2022) – Braintale receives the Robert D. Zimmerman Scientific Prize for expanding the use of its digital platform to identify patients with Alzheimer’s disease

STRASBOURG, France, August 23, 2022–(BUSINESS WIRE)–Braintale, a medtech deciphering white matter, a spin-off from Hôpitaux du Grand Paris, has been rewarded by the scientific committee of the 34th Eastern NeuroRadiology Society (ENRS), whose annual congress was held in Burlington (Virginia, United States) from August 19 to 21, 2022, the Robert D. Zimmerman Scientific Prize for his communication. Entitled Differentiating patients with Alzheimer’s disease and mild cognitive impairment: contributions of digital DTI biomarkers available in clinical practice the communication was presented by Vincent Perlbarg, co-founder, president and CSO of the company.

Long underestimated in neuroscience, the white matter, which represents 80% of the human brain, plays a key role in its proper functioning, development and aging, whether normal or pathological. Thus, Braintale has been developing since its creation in 2018 non-invasive, accessible, effective and clinically validated measurement and prediction solutions for doctors treating patients suffering from brain diseases.

Using data available from the ADNI (Alzheimer’s Disease Neuroimaging Initiative), the objective of this study was to test whether standardized DTI biomarkers, in addition to MRI volumetry, could discriminate patients diagnosed with Alzheimer’s disease from age-matched healthy controls and subjects with mild cognitive impairment. (MCI). Results showed a significant improvement (p

This is the first proof of the relevance of the Braintale platform to allow better management of patients with Alzheimer’s disease, reinforced by the Robert D. Zimmerman scientific prize awarded by the scientific committee of the ENRS. Alzheimer’s disease and related dementias affect more than 36 million people worldwide, with more than 7 million new diagnoses each year. Over 500 clinical studies are actively recruiting patients1making this therapeutic area one of the main value drivers of CNS research and development.

Alterations in white matter have already been observed in the early stage of Alzheimer’s disease, in particular using diffusion tensor imaging, but the clinical translation of significant biomarkers remains a major unresolved challenge to date. Complementary to existing CSF and blood biomarkers, white matter biomarkers can now be considered early markers of Alzheimer’s disease while also being considered potentially important pathophysiological features. A better understanding of white matter alterations will be very important for new therapies under development.

Braintale’s digital medical device platform now enables non-invasive management of aging patients in daily clinical practice. Its specifications support patient segmentation and differentiated diagnosis, as well as increasing clinical trial success rates by providing efficient research-to-clinic translation of meaningful white matter biomarkers.

Vincent Perlbarg comments, “This study suggests that standardized DTI biomarkers show significant benefit in monitoring white matter alterations to improve the management of pathological aging by distinguishing the patient population with documented diagnoses. The easy implementation of these biomarkers in the clinic opens up the potential of this approach to aid patient management in the clinical setting and potentially as a surrogate endpoint in clinical trials. »

About Braintale

Braintale is an innovative medical technology company that deciphers white matter to enable better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarker platform to support clinical decision-making. Braintale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, particularly for demyelinating diseases, amyotrophic lateral sclerosis and neurodegenerative diseases. Based on more than 15 years of research and development, Braintale products are developed to meet the medical needs and expectations of healthcare professionals for the benefit of patients.

Since its inception in 2018, the company has implemented a comprehensive quality management system and is now ISO 13485:2016 certified, with a suite of products available to the European market under the European Medical Device Regulation ( LOL).

For more information, visit www.braintale.eu.

1 Clinicaltrials.gov, 548 Alzheimer’s Disease Recruitment Studies as of August 22, 2022.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220823005379/en/

contacts

Braintale – Julie Rachline, CEO
julie.rachline@braintale.eu +33 6 62 42 03 58